GlassScriptPhysician profile
Louis Hite
NPI 1265434013
$2,053.45
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.85 · 2020: $11.64 · 2021: $572 · 2022: $720 · 2023: $595 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $208.59 | 2023 | Sunosi |
| Abbvie INC. | $196.79 | 2021-2023 | |
| Lilly USA, LLC | $157.02 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $131.85 | 2021-2022 | |
| Baxter Healthcare | $115.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.52 | 2021 | |
| Novo Nordisk INC | $108.24 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $104.42 | 2021-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.47 | 2022-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $90.78 | 2021-2022 | |
| Esperion Therapeutics, INC. | $88.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $83.17 | 2020-2024 | Farxiga |
| Abbott Laboratories | $80.30 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $58.74 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.88 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $30.88 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $29.58 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $25.08 | 2021-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $23.83 | 2021 | |
| Boston Scientific Corporation | $22.09 | 2024 | Wavewriter Alpha Prime 16 |
| Eisai INC. | $17.93 | 2021 | |
| Harmony Biosciences LLC | $17.79 | 2023 | Wakix |
| Edwards Lifesciences Corporation | $17.49 | 2022 | |
| Pfizer INC. | $16.43 | 2023 | |
| Amgen INC. | $15.85 | 2019 | |
| Amarin Pharma, INC. | $15.47 | 2021 | |
| Endo Pharmaceuticals INC. | $14.13 | 2021 | |
| Daiichi Sankyo INC. | $13.55 | 2024 | Injectafer |
| Arbor Pharmaceuticals, INC. | $13.09 | 2021 | |
| Exact Sciences Corporation | $12.87 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Hite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.